Silver Book Fact

An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.

Jaglal, Susan B., Ian Weller, Muhammad Mamdani, Gillian Hawker, Hans Kreder, Liisa Jaakkimainen, and Jonathan Adachi. Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the hip fracture projections wrong?. Arch Intern Med. 2005; 159(11): 1215-20. http://www.ncbi.nlm.nih.gov/pubmed/15883628

Reference

Title
Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the hip fracture projections wrong?
Publication
Arch Intern Med
Publication Date
2005
Authors
Jaglal, Susan B., Ian Weller, Muhammad Mamdani, Gillian Hawker, Hans Kreder, Liisa Jaakkimainen, and Jonathan Adachi
Volume & Issue
Volume 159, Issue 11
Pages
1215-20
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is…  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.